Raiffeisen Bank International AG Has $41,000 Stock Holdings in Waters Corporation $WAT

Raiffeisen Bank International AG decreased its stake in Waters Corporation (NYSE:WAT) by 97.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111 shares of the medical instruments supplier’s stock after selling 4,744 shares during the period. Raiffeisen Bank International AG’s holdings in Waters were worth $41,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of WAT. Pilgrim Global Advisors LLC acquired a new position in Waters during the second quarter valued at approximately $466,131,171,000. BlackRock Inc. acquired a new position in shares of Waters during the 2nd quarter worth approximately $3,182,191,000. Jupiter Topco LLC acquired a new position in shares of Waters during the 2nd quarter worth approximately $623,921,000. Janus Henderson Group PLC raised its stake in shares of Waters by 27.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,638,772 shares of the medical instruments supplier’s stock worth $488,028,000 after purchasing an additional 348,379 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Waters by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock worth $602,921,000 after purchasing an additional 8,590 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Stock Up 0.0%

Shares of WAT opened at $409.39 on Monday. The firm has a market cap of $40.22 billion, a P/E ratio of 102.09, a price-to-earnings-growth ratio of 2.38 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86. Waters Corporation has a 52 week low of $282.77 and a 52 week high of $426.22. The firm’s 50-day simple moving average is $391.93 and its 200 day simple moving average is $351.64.

Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.62 billion. During the same period last year, the business posted $2.95 earnings per share. The business’s revenue for the quarter was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, analysts forecast that Waters Corporation will post 14.56 earnings per share for the current year.

Key Headlines Impacting Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Shares are up 3.1% since the company’s most recent earnings report, reflecting investor confidence after Waters exceeded quarterly expectations with adjusted EPS of $3.05 versus the $3.01 consensus and revenue of $1.65 billion versus $1.62 billion expected. Why Is Waters Up Since Last Earnings Report?
• Positive Sentiment: Analysts currently assign Waters a consensus recommendation of “Moderate Buy,” providing continued support for the stock. The company also maintained 2026 earnings guidance of $14.45 to $14.65 per share. Waters Given Moderate Buy Recommendation
• Neutral Sentiment: Waters’ latest results included strong reported year-over-year revenue growth and an earnings beat, but investors may focus on whether that momentum is sustainable and whether the company can deliver its full-year outlook.
• Negative Sentiment: The stock trades at a very elevated valuation—approximately 102 times earnings—so expectations are high. Any weaker-than-expected demand, guidance revision, or margin pressure could produce volatility despite the positive analyst consensus.

Insiders Place Their Bets

In other Waters news, Director Christopher Kuebler sold 3,626 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the transaction, the director directly owned 17,808 shares of the company’s stock, valued at $7,086,515.52. This represents a 16.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on WAT shares. Sanford C. Bernstein assumed coverage on shares of Waters in a research note on Friday, June 26th. They issued an “outperform” rating and a $435.00 target price for the company. The Goldman Sachs Group upped their price target on shares of Waters from $380.00 to $425.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Piper Sandler upgraded shares of Waters from a “neutral” rating to an “overweight” rating and increased their price target for the company from $400.00 to $480.00 in a research note on Thursday, August 27th. Royal Bank Of Canada lifted their price objective on shares of Waters from $435.00 to $475.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company boosted their price objective on shares of Waters from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $424.35.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.